AngioDynamics (NASDAQ:ANGO) Reaches New 12-Month High - Here's What Happened

Key Points

• AngioDynamics shares reached a new 52-week high, trading as high as $15.73 and closing around $15.53, with the stock up 1.7% during the session.
• Analyst sentiment remains mixed: Canaccord Genuity and HC Wainwright raised their price targets to $20 and $19, respectively, while Zacks downgraded the stock to “strong sell.” The overall consensus rating is “Hold,” with an average price target of $19.50.
• AngioDynamics beat quarterly expectations, reporting an adjusted loss of $0.07 per share versus the projected $0.11 loss and revenue of $86.61 million versus the $80.24 million estimate. However, the company remains unprofitable, with a negative net margin of 11.48%.

AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $15.73 and last traded at $15.5250, with a volume of 405873 shares traded. The stock had previously closed at $15.69.

Analyst Ratings Changes

A number of brokerages recently commented on ANGO. Canaccord Genuity Group increased their price objective on shares of AngioDynamics from $16.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Weiss Ratings restated a "sell (d-)" rating on shares of AngioDynamics in a research report on Friday, July 17th. Zacks Research downgraded shares of AngioDynamics from a "hold" rating to a "strong sell" rating in a report on Thursday, July 16th. Finally, HC Wainwright increased their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, AngioDynamics currently has an average rating of "Hold" and an average target price of $19.50.

AngioDynamics Stock Up 1.7%

The firm has a market capitalization of $659.79 million, a PE ratio of -18.31 and a beta of 0.33. The business's fifty day moving average price is $13.16 and its 200 day moving average price is $11.68.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.04. The business had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. As a group, sell-side analysts forecast that AngioDynamics, Inc. will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the firm's stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the sale, the senior vice president owned 64,745 shares in the company, valued at $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On AngioDynamics

Several institutional investors have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC lifted its position in AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier's stock worth $26,000 after buying an additional 1,199 shares during the period. Kemnay Advisory Services Inc. acquired a new position in shares of AngioDynamics during the 4th quarter valued at about $27,000. State of Wyoming acquired a new position in shares of AngioDynamics during the 2nd quarter valued at about $31,000. Russell Investments Group Ltd. lifted its holdings in shares of AngioDynamics by 329.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier's stock worth $47,000 after acquiring an additional 3,213 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of AngioDynamics by 359.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier's stock worth $54,000 after acquiring an additional 4,268 shares during the period. 89.43% of the stock is currently owned by institutional investors and hedge funds.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company's products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source